CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
In the year-ago period, the company incurred a loss of $1.41 per share. Total revenues, though negligible, were entirely from grant revenues, which amounted to $0.6 million in the quarter. The reported figure significantly missed the Zacks Consensus Estimate of $6.4 million. CRSP did not generate revenues during the year-ago period. Research and development expenses fell 9% year over year to $82.2 million. This was due to reduced variable external research and manufacturing costs. General and administrative expenses declined 5% year over year to $17.4 million in the quarter. Collaboration expenses in the quarter amounted to $11.2 million, down 52% year over year. The downside was primarily due to the time it took to reach the deferral limit on costs related to the Casgevy program. As of Sept. 30, 2024, the company had cash, cash equivalents, marketable securities and accounts receivables of $1.9 billion compared with $2.0 billion as of June 30, 2024. Shares of CRISPR Thera
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]Yahoo! Finance
- Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? [Yahoo! Finance]Yahoo! Finance
- 3 Monster Stocks in the Making [Yahoo! Finance]Yahoo! Finance
- Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by Advances in CRISPR and Gene Therapies – SNS Insider [Yahoo! Finance]Yahoo! Finance
- The Gene Revolution: Transforming Lives through Gene Editing Therapeutics [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 11/5/24 - Beat
CRSP
Sec Filings
- 11/13/24 - Form 4
- 11/12/24 - Form 144
- 11/5/24 - Form 10-Q
- CRSP's page on the SEC website